Safety of High-Dose Intravenous Daptomycin Treatment: Three-Year Cumulative Experience in a Clinical Program
Background.There are limited safety data for high-dose and long-term daptomycin treatment (>6mg/kg administered for ⩾14 days). We present our experience in 61 patients. Methods.We performed a retrospective chart review for all patients treated with daptomycin at New York Hospital Queens (Flushing...
Saved in:
Published in | Clinical infectious diseases Vol. 49; no. 2; pp. 177 - 180 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
The University of Chicago Press
15.07.2009
University of Chicago Press Oxford University Press |
Subjects | |
Online Access | Get full text |
ISSN | 1058-4838 1537-6591 1537-6591 |
DOI | 10.1086/600039 |
Cover
Summary: | Background.There are limited safety data for high-dose and long-term daptomycin treatment (>6mg/kg administered for ⩾14 days). We present our experience in 61 patients. Methods.We performed a retrospective chart review for all patients treated with daptomycin at New York Hospital Queens (Flushing) from 1 January 2004 through 30 April 2007; patients were identified through a computerized hospital pharmacy database. Results.Sixty-one patients (29 male and 32 female patients; mean age, 66.6 years) received a mean dose of 8 mg/kg of daptomycin for a median of 25 days (range, 14-82 days). Twelve patients (with bone and skin and soft-tissue infections) did not have an identified microbiologic isolate. Gram-positive infections included bloodstream infection with or without infective endocarditis (n=32), skin and soft-tissue infection (n=14), bone and joint infection (n=9), and intra-abdominal infection (n=5), and unidentified infection (n=1). Prosthetic devices were removed from 11 of 20 patients. Grade 1 adverse events occurred in 22 patients and did not lead to daptomycin discontinuation. Fifty-eight patients underwent creatine phosphokinase (CPK) analysis (34 patients had paired CPK analyses at the beginning of and during therapy, and 13 patients had random CPK analysis performed during treatment). Three patients had constitutional and/or musculoskeletal symptoms accompanying CPK levels >10 times upper limit of normal (grade 3). All occurred after 24 days of treatment and improved after daptomycin treatment was discontinued. Two of 3 patients were morbidly obese (body mass index grade III). Conclusions.Daptomycin treatment was well tolerated at a mean dose of 8 mg/kg for a median duration of 25 days. The incidence of symptomatic CPK level elevation was within the range reported with lower doses of daptomycin and/or for shorter treatment durations. |
---|---|
Bibliography: | ark:/67375/HXZ-M71Q2781-V istex:A74F77DAD9C7311425551FDF19FBCA4D55B5DF24 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
ISSN: | 1058-4838 1537-6591 1537-6591 |
DOI: | 10.1086/600039 |